Fieldpoint Private Securities LLC boosted its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 33.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,386 shares of the biopharmaceutical company’s stock after acquiring an additional 594 shares during the period. Fieldpoint Private Securities LLC’s holdings in Alexion Pharmaceuticals were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in ALXN. Ameriprise Financial Inc. boosted its holdings in Alexion Pharmaceuticals by 3.5% in the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock worth $896,491,000 after purchasing an additional 215,005 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Alexion Pharmaceuticals in the third quarter worth $357,000. Catalyst Capital Advisors LLC acquired a new position in Alexion Pharmaceuticals in the third quarter worth $694,000. Pacer Advisors Inc. boosted its holdings in Alexion Pharmaceuticals by 14.0% in the third quarter. Pacer Advisors Inc. now owns 7,684 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 942 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its holdings in Alexion Pharmaceuticals by 46.6% in the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 4,293 shares of the biopharmaceutical company’s stock worth $602,000 after purchasing an additional 1,365 shares during the period. 95.34% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $123.97 on Tuesday. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. The firm has a market cap of $28,098.12, a PE ratio of 62.26, a P/E/G ratio of 1.17 and a beta of 1.13.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same period in the previous year, the business earned $1.26 earnings per share. The company’s revenue was up 9.5% on a year-over-year basis. research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.

In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 3,363 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $115.70, for a total value of $389,099.10. Following the sale, the executive vice president now directly owns 71,400 shares in the company, valued at $8,260,980. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the sale, the senior vice president now owns 32,635 shares in the company, valued at $3,826,780.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,253 shares of company stock worth $3,656,229. 4.35% of the stock is owned by company insiders.

A number of equities analysts have commented on ALXN shares. BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Citigroup decreased their price objective on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a report on Friday, February 9th. SunTrust Banks set a $172.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, February 12th. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have given a buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $155.22.

TRADEMARK VIOLATION NOTICE: “Fieldpoint Private Securities LLC Grows Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/03/20/fieldpoint-private-securities-llc-grows-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.